Loading...
Loading...
Browse all stories on DeepNewz
VisitWill VTAMA Cream receive FDA approval for AtD by end of 2024?
Yes • 50%
No • 50%
FDA approval announcements and press releases
Organon to Acquire Dermavant for Up to $1.2 Billion with $175 Million Upfront
Sep 18, 2024, 01:15 PM
Organon has announced its acquisition of Dermavant Sciences, a subsidiary of Roivant Sciences, in a deal valued at up to $1.2 billion. The acquisition includes Dermavant's innovative dermatologic therapy, VTAMA (tapinarof) Cream, 1%. The terms of the deal involve an upfront payment of $175 million, with additional payments contingent on regulatory approval and sales milestones, potentially reaching a total of $1.2 billion. This includes $75 million on approval in AtD. Roivant's stock rose by 2.2% pre-market following the announcement. This strategic move is seen as positive for Roivant, while analysts have mixed opinions on its impact on Organon.
View original story
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
Granted in 2024 • 25%
Granted in 2025 • 25%
Not granted by 2025 • 25%
Other designation received • 25%
Full Approval • 25%
Accelerated Approval • 25%
Conditional Approval • 25%
Rejection • 25%
Hold • 25%
Sell • 25%
Strong Buy • 25%
Buy • 25%
$800 million to $1 billion • 25%
Less than $500 million • 25%
More than $1 billion • 25%
$500 million to $799 million • 25%